New options for the treatment of patients with uncontrolled course of chronic rhinosinusitis with nasal polyps with dupilumab: a clinical case

Background. Treatment of T2 inflammation-mediated chronic rhinosinusitis with nasal polyps is considered a challenge for doctors of various specialties - otorhinolaryngologists, allergists and pulmonologists. The introduction of biological therapy has become an advantageous and promising method of treating such patients. Description of the clinical case. The article describes a clinical case of a patient suffering from severe chronic rhinosinusitis with nasal polyps with interruption of biological therapy. The patient underwent many surgical interventions without a lasting effect. Severe symptoms significantly affected the quality of life and the woman's ability to work. Stable positive dynamics was achieved only when receiving subcutaneous injections of the drug dupilumab 300 mg every 2 weeks. Biological therapy was canceled due to problems with the equipment of the hospital, and the symptoms began to return after 2 months. The resumption of treatment had a rapid effect, as reflected by the results of the SNOT-22 questionnaire, endoscopy of the nasal cavity, computed tomography of the paranasal sinuses. Conclusion. Biological therapy is an effective treatment for patients with T2 inflammation-induced diseases, including chronic rhinosinusitis with nasal polyps. Nevertheless, this type of therapy gives the proper positive effect only in the case of continuous use of the drug; when it is canceled, the symptoms tend to return.

chronic rhinosinusitis with nasal polyps, monoclonal antibody, dupilumab, T2 inflammation, clinical case